TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05735340

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Diabetes Education
Description: Participants in this arm will receive traditional diabetes education over 5 sessions in the first 3 months of participation and be followed for 6 months.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: T1DES
Description: Participants in this arm will receive the T1DES behavioral interventions over 5 sessions in the first 3 months of participation and be followed for 6 months.
Study: NCT06380751

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribociclib
Description: CDK4/6 Inhibitor

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Palbociclib
Description: CDK 4/6 Inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib
Description: CDK 4/6 Inhibitor

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fulvestrant
Description: Endocrine Therapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Letrozole
Description: Endorcine Therapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anastrozole
Description: Endocrine Therapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Exemestane
Description: Endocrine Therapy
Study: NCT06246643

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regorafenib (Stivarga, BAY73-4506)
Description: Participants will be treated with the regorafenib dose taken during the last cycle of the feeder study. Adult participants will receive either 60, 80, 90, 120, or 160 mg orally (p.o.) once daily (qd) for 3 weeks of every 4-week cycle (i.e. 3 weeks on, 1 week off). Pediatric participants will receive 82 mg/m\^2 p.o. qd for 14 days, in a 14 days on/7 days off schedule (21-day cycle).
Study: NCT04849416

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LOXO-305
Description: Administered orally.
Study: NCT05564390

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Given IV or SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Given IV or SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Given IV or SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Given IV or SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Given IV or SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Given IV or SC

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Best Practice
Description: Receive SOC treatment

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo biopsy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biopsy
Description: Undergo biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo biopsy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biospecimen Collection
Description: Undergo collection of blood samples

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of blood samples

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of blood samples

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of blood samples

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of blood samples

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biospecimen Collection
Description: Undergo collection of blood samples

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of blood samples

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of blood samples

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of blood samples

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biospecimen Collection
Description: Undergo collection of blood samples
Study: NCT04832516

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Performing following WHO (World Health Organization)
Description: The CLA group will perform exercises following WHO (World Health Organization) prescription

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Performing on their needs
Description: The IND group will perform strength, aerobic or flexibility exercises depending on their needs observed during the first assessment.
Study: NCT04847141

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: C19-IG 20%
Description: Anti-COVID-19 Immune Globulin (Human) 20%

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: C19-IG 20%
Description: Anti-COVID-19 Immune Globulin (Human) 20%

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.9% Sodium chloride
Description: C19-IG 20% matching placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% Sodium chloride
Description: C19-IG 20% matching placebo
Study: NCT04963634

Intervention type: OTHER
Intervention: Biobanking
Description: For patients included in BRADYDIAG study, 2 blood samples will be collected at enrollment (for group 1: bradykinin angioedema and for group 2: histamine-mediated angioedema) and at 1 year visit (for group 1 only: bradykinin angioedema).

Intervention type: OTHER
Intervention: Biobanking
Description: For patients included in BRADYDIAG study, 2 blood samples will be collected at enrollment (for group 1: bradykinin angioedema and for group 2: histamine-mediated angioedema) and at 1 year visit (for group 1 only: bradykinin angioedema).
Study: NCT06263790

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intubating laryngeal mask
Description: Intubation through a laryngeal mask

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Direct laryngoscopy
Description: Intubation by using a direct laryngoscope
Study: NCT05560919

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dihydroxycholecalciferols
Description: Injection of Dihydroxycholecalciferols solution in the periodontal ligament for lower anterior segment teeth.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: dimethyl sulfoxide
Description: Injection of dimethyl sulfoxide in the periodontal ligament for lower anterior segment teeth.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: serum
Description: Injection of serum in the periodontal ligament for lower anterior segment teeth.
Study: NCT06128070

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Chest Computed Tomography
Description: Undergo chest CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Echocardiography
Description: Undergo ECHO

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hematopoietic Cell Transplantation
Description: Undergo HCT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Multigated Acquisition Scan
Description: Undergo MUGA

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib Phosphate
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Given IV
Study: NCT05564390

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biospecimen Collection
Description: Undergo collection of blood samples
Study: NCT04359225

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 3D Telemedicine
Description: Telemedicine using 3D broadcast to clinician

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: 2D Telemedicine
Description: Standard care with 2D telemedicine
Study: NCT04758975

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: VENETOCLAX: Ramp-up than 400 mg QD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: RITUXIMAB: Cycle 7 Day 1 375 mg/m2; Cycles 8-12 Day 1 500 mg/m2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: IBRUTINIB 420 mg QD
Study: NCT04471974

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BET Bromodomain Inhibitor ZEN-3694
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BET Bromodomain Inhibitor ZEN-3694
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BET Bromodomain Inhibitor ZEN-3694
Description: Given PO
Study: NCT05564390

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of blood samples
Study: NCT04471974

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzalutamide
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzalutamide
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzalutamide
Description: Given PO

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV
Study: NCT06049459

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Optical Correction
Description: Optical correction (if needed)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Optical Correction
Description: Optical correction (if needed)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Therapeutic Dichoptic Virtual Reality Games
Description: Virtual Reality Game play for amblyopia treatment
Study: NCT06094114

Intervention type: DEVICE
Intervention: pacemaker follow-up
Description: Performance of an exercise test in patients previously implanted with Micra AV
Study: NCT05094804

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OR2805
Description: IgG1 monoclonal antibody that binds specifically to the CD163 protein.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OR2805
Description: IgG1 monoclonal antibody that binds specifically to the CD163 protein.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OR2805
Description: IgG1 monoclonal antibody that binds specifically to the CD163 protein.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cemiplimab
Description: IgG4 mAb that binds to PD-1 and blocks its interaction with PD-L1 and PD-L2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cemiplimab
Description: IgG4 mAb that binds to PD-1 and blocks its interaction with PD-L1 and PD-L2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: An antineoplastic agent that acts by disrupting the microtubular network in cells that is essential for mitotic and interphase cellular functions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: An antineoplastic agent that acts by disrupting the microtubular network in cells that is essential for mitotic and interphase cellular functions.
Study: NCT05250518

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: argon plasma coagulation
Description: After hot snare polypectomy, participants will be randomized assigned to the APC group for argon plasma coagulation to prevent colorectal post-procedure bleeding.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: clip closure
Description: After hot snare polypectomy, participants will be randomized assigned to the Clip group for complete closure(spacing between adjacent clips \< 1cm) to prevent colorectal post-procedure bleeding.
Study: NCT05212402

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Cannabinol
Description: Prospective,1:1 randomization and stratified by birth sex, and double-blinded to the condition of subjects.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Prospective,1:1 randomization and stratified by birth sex, and double-blinded to the condition of subjects.
Study: NCT05646719

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phentolamine Opthalmic Solution 0.75%
Description: phentolamine ophthalmic solution 0.75% (Nyxol), a non-selective alpha-1 and alpha-2 adrenergic antagonist

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phentolamine Opthalmic Solution 0.75%
Description: phentolamine ophthalmic solution 0.75% (Nyxol), a non-selective alpha-1 and alpha-2 adrenergic antagonist

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Vehicle for Phentolamine Ophthalmic Solution

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Vehicle for Phentolamine Ophthalmic Solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low dose pilocarpine
Description: Pilocarpine hydrochloride ophthalmic solution 0.4%

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low dose pilocarpine
Description: Pilocarpine hydrochloride ophthalmic solution 0.4%

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low dose pilocarpine vehicle
Description: Vehicle for low dose pilocarpine

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low dose pilocarpine vehicle
Description: Vehicle for low dose pilocarpine
Study: NCT05076994

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise therapy
Description: A series of home exercise videos to improve patient adherence to exercise prescription

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Care
Description: An exercise prescription and verbal instructions in clinic
Study: NCT05166603

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TeleGRACE
Description: Patients receive a virtual home visit and care from the GRACE team
Study: NCT05515445

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chiglitazar
Description: Oral single dose 48 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chiglitazar
Description: Oral single dose 48 mg
Study: NCT05564390

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Multigated Acquisition Scan
Description: Undergo MUGA

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Multigated Acquisition Scan
Description: Undergo MUGA

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Multigated Acquisition Scan
Description: Undergo MUGA

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Multigated Acquisition Scan
Description: Undergo MUGA
Study: NCT05460689

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: M-HEALTH APP
Description: The intervention group will have in use a mHealth App for education and support of caregivers of children undergoing tonsillectomy and/or adenoidectomy in the perioperative process. An out-patient nurse will be in charge of instructing intervention group participants to mHealth App use and content options. The mHealth App will be available for intervention group families from the day of pre-admission visits to the 7th day post surgery or follow up visit.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Standard Care
Description: The control group will receive information and education provided by nurses and physician in the preoperative visits and during hospitalization. Information and education will be provided orally or through printed booklets.
Study: NCT04862741

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NX-13 250mg IR
Description: Subjects will take study drug by ingesting one tablet per day, recommended at the same time in the morning for consistency. Subjects in a NX-13 group will receive either 250 mg or 500 mg of NX-13 in an immediate release or modified release tablet and subjects in the placebo group will receive matched placebo.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NX-13 500mg IR
Description: Subjects will take study drug by ingesting one tablet per day, recommended at the same time in the morning for consistency. Subjects in a NX-13 group will receive either 250 mg or 500 mg of NX-13 in an immediate release or modified release tablet and subjects in the placebo group will receive matched placebo.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NX-13 500mg MR
Description: Subjects will take study drug by ingesting one tablet per day, recommended at the same time in the morning for consistency. Subjects in a NX-13 group will receive either 250 mg or 500 mg of NX-13 in an immediate release or modified release tablet and subjects in the placebo group will receive matched placebo.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will take study drug by ingesting one tablet per day, recommended at the same time in the morning for consistency. Subjects in a NX-13 group will receive either 250 mg or 500 mg of NX-13 in an immediate release or modified release tablet and subjects in the placebo group will receive matched placebo.
Study: NCT04709874

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Paravertebral block
Description: Paravertebral block using nerve stimulator guidance will be done at C7-T1

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Suprascapular block
Description: Paravertebral block using nerve stimulator guidance will be done
Study: NCT05143918

Intervention type: OTHER
Intervention: assessment of quality of life using questionnaire
Description: assessment of quality of life in hypothyroid patients using SF 36 questionnaire

Intervention type: OTHER
Intervention: assessment of quality of life using questionnaire
Description: assessment of quality of life in hypothyroid patients using SF 36 questionnaire
Study: NCT05430204

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Group 1: one-hour GCT
Description: Group I will be comprised of one-hour 50g glucose challenge participants for diagnosis of GDM..Diagnosis will be based on 1-hour glucose challenge test results: 1-hour result ≤ 130 mg/dL, the participant will have passed the challenge test. 1-hour result ≥ 130 mg/dL will complete a three-hour 100g glucose tolerance test. If two out of three values are elevated per Carpenter Coustan criteria , the participant will be diagnosed with GDM and treated according to the standard of care. This group will also receive the CGM.CGM data will not be observed until completion of study and will not be available to provider. Participants will return transmitter at follow up visit after completion of 7 days.Group I will receive routine prenatal care follow-up depending upon one-hour glucose results as written above.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Group 2: CGM placement
Description: CGM will consist of using the Dexcom G6 Pro device. The device will be placed on the abdomen or the arm.The Dexcom G6/G7 Pro App will be downloaded on the patient's phone. A patient profile will be created on the Dexcom Clarity portal .The patient will receive an email to link their portal to the clinic's portal.The patient will receive a message through Epic electronic medical records to remove the CGM 10 days after placement.The device will be reviewed by the Diabetes team 48 hours after CGM is removed. The recommended range for glucose during pregnancy is defined as 63-140 mg/dL .The time above range has been defined as ≥ 140 mg/dL, greater than 10% of total CGM placement time. The following criteria will currently be used to diagnose gestational diabetes in the CGM group:~* Time above range (≥140 mg/dL) ≥ 10% of the time while using CGM or~* Average glucose≥130 mg/dL or~* Any glucose value ≥200 mg/dL
Study: NCT06086236

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous Auricular Vagus Nerve Stimulation
Description: Through a special Ear set, bilateral Transcutaneous Auricular Vagus Nerve Stimulation was applied to all participants for 20 minutes.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous Auricular Vagus Nerve Stimulation
Description: Through a special Ear set, bilateral Transcutaneous Auricular Vagus Nerve Stimulation was applied to all participants for 20 minutes.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous Auricular Vagus Nerve Stimulation
Description: Through a special Ear set, bilateral Transcutaneous Auricular Vagus Nerve Stimulation was applied to all participants for 20 minutes.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous Auricular Vagus Nerve Stimulation
Description: Through a special Ear set, bilateral Transcutaneous Auricular Vagus Nerve Stimulation was applied to all participants for 20 minutes.
Study: NCT05564390

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Multigated Acquisition Scan
Description: Undergo MUGA

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Multigated Acquisition Scan
Description: Undergo MUGA

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Multigated Acquisition Scan
Description: Undergo MUGA

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Multigated Acquisition Scan
Description: Undergo MUGA
Study: NCT06055530

Intervention type: DIAGNOSTIC_TEST
Intervention: Artificial Intelligence Digital Pathology
Description: School aged children will be asked to leave a stool sample. The samples will be prepared with the Kato-Katz method and scanned and processed by an artificial intelligence digital pathology system to determine the infection level of soil transmitted helminths and schistosomiasis. The samples will also be analyzed by a human microscopist for comparison.

Intervention type: DIAGNOSTIC_TEST
Intervention: Artificial Intelligence Digital Pathology
Description: School aged children will be asked to leave a stool sample. The samples will be prepared with the Kato-Katz method and scanned and processed by an artificial intelligence digital pathology system to determine the infection level of soil transmitted helminths and schistosomiasis. The samples will also be analyzed by a human microscopist for comparison.
Study: NCT05932381

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Complete decongestive therapy
Description: the patients will receive Complete decongestive therapy in the form of intermittent pneumatic compression, Exercising, bandaging, and manual lymphatic drainage with Pressures of 50, 80, and 120 mmHg and timing 5, 20, and 50 secs

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medical treatment
Description: the patients will receive routine medical treatment